{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:47:07Z","timestamp":1765234027304,"version":"build-2065373602"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Immune checkpoint inhibitors (ICIs) ushered in a new era in cancer treatment, but alongside their efficacy is an adverse event profile that involves the immune system as a whole and may impact several organs. Case Presentation: We present the case of a 68-year-old woman with a diagnosis of cervical cancer treated with pembrolizumab who developed progressively steroid-refractory chronic diarrhea and ensuing visual problems. Topical antibiotics failed to heal a corneal ulcer in the left eye, necessitating evisceration. Imaging showed intestinal pneumatosis without ischemia, and there was immediate clinical improvement after initiation of corticosteroid therapy. This clinical picture\u2014steroid-dependent colitis and immune-mediated uveitis associated with secondary bacterial infection\u2014was coded as an immune-related adverse event (irAE) resulting from ICI treatment. Because of the prompt and complete regression of the symptoms upon corticosteroid therapy, this was considered as a criterion for the final diagnosis. Conclusions: The case highlights the complexity and potential severity of irAEs that need to be appropriately identified and promptly managed by multidisciplinary teams.<\/jats:p>","DOI":"10.3390\/reports8030154","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T14:46:04Z","timestamp":1755787564000},"page":"154","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitor-Induced Ocular Toxicity: A Case of Pembrolizumab-Associated Corneal Ulceration and Evisceration"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5308-7072","authenticated-orcid":false,"given":"Mario","family":"Caldarelli","sequence":"first","affiliation":[{"name":"General Medicine and Aging Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy"},{"name":"Department of Medical and Surgical Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-0093","authenticated-orcid":false,"given":"Donatella","family":"Brisinda","sequence":"additional","affiliation":[{"name":"General Medicine and Aging Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy"},{"name":"Department of Aging, Orthopedic and Rheumatologic Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"De Matteis","sequence":"additional","affiliation":[{"name":"General Medicine and Aging Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy"},{"name":"Department of Aging, Orthopedic and Rheumatologic Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-7628","authenticated-orcid":false,"given":"Francesco","family":"De Vito","sequence":"additional","affiliation":[{"name":"General Medicine and Aging Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy"},{"name":"Department of Aging, Orthopedic and Rheumatologic Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Gambini","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Catholic University of the Sacred Heart, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5378-8442","authenticated-orcid":false,"given":"Rossella","family":"Cianci","sequence":"additional","affiliation":[{"name":"General Medicine and Aging Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy"},{"name":"Department of Medical and Surgical Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Gambassi","sequence":"additional","affiliation":[{"name":"General Medicine and Aging Unit, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy"},{"name":"Department of Medical and Surgical Sciences, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-Related Ocular Toxicities in Solid Tumor Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review","volume":"17","author":"Oweira","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina Phila."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Iranzo, P., Callejo, A., Assaf, J.D., Molina, G., Lopez, D.E., Garcia-Illescas, D., Pardo, N., Navarro, A., Martinez-Marti, A., and Cedres, S. (2022). Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front. Med., 9.","DOI":"10.3389\/fmed.2022.875974"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., and Bian, Y. (2023). Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"113501","DOI":"10.1016\/j.ejca.2023.113501","article-title":"The Future of Targeting Cytotoxic T-Lymphocyte-Associated Protein-4: Is There a Role?","volume":"198","author":"Lahn","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1\/PD-L1 Anticancer Immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to Select IgG Subclasses in Developing Anti-Tumor Therapeutic Antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40135-023-00312-z","article-title":"Update on Immune Checkpoint Inhibitor-Associated Uveitis","volume":"11","author":"Kim","year":"2023","journal-title":"Curr. Ophthalmol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12348-023-00338-1","article-title":"Relation between Ocular Paraneoplastic Syndromes and Immune Checkpoint Inhibitors (ICI): Review of Literature","volume":"13","author":"Casselman","year":"2023","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.18240\/ijo.2022.04.19","article-title":"Immune Checkpoint Inhibitor-Associated Ophthalmic Adverse Events: Current Understanding of Its Mechanisms, Diagnosis, and Management","volume":"15","author":"Zhou","year":"2022","journal-title":"Int. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhang, H., Houadj, L., Wu, K.Y., and Tran, S.D. (2024). Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review. Diagnostics, 14.","DOI":"10.3390\/diagnostics14030336"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/1346-8138.13612","article-title":"Case of Acute Anterior Uveitis and Vogt\u2013Koyanagi\u2013Harada Syndrome-like Eruptions Induced by Nivolumab in a Melanoma Patient","volume":"44","author":"Arai","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_16","first-page":"62","article-title":"Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments","volume":"1","author":"Li","year":"2025","journal-title":"Med. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/0113892029308327240612110334","article-title":"Emerging Multi-Omic Approaches to the Molecular Diagnosis of Mitochondrial Disease and Available Strategies for Treatment and Prevention","volume":"25","author":"Khaghani","year":"2024","journal-title":"Curr. Genom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1874467215666220324114624","article-title":"Immunomodulatory Therapeutic Effects of Curcumin on M1\/M2 Macrophage Polarization in Inflammatory Diseases","volume":"16","author":"Abdollahi","year":"2023","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_19","first-page":"e060923220758","article-title":"At the Crossroads of TNF \u03b1 Signaling and Cancer","volume":"17","author":"Manohar","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cpan.2024.12.001","article-title":"Emerging Trends and Hot Topics in the Application of Multi-Omics in Drug Discovery: A Bibliometric and Visualized Study","volume":"21","author":"Wang","year":"2024","journal-title":"Curr. Pharm. Anal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/OTT.S65802","article-title":"Tremelimumab: Research and Clinical Development","volume":"23","author":"Ibarrondo","year":"2016","journal-title":"OncoTargets Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e000889","DOI":"10.1136\/bmjophth-2021-000889","article-title":"Autoimmune Retinopathy with Associated Anti-Retinal Antibodies as a Potential Immune-Related Adverse Event Associated with Immunotherapy in Patients with Advanced Cutaneous Melanoma: Case Series and Systematic Review","volume":"7","author":"Heng","year":"2022","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/09273948.2022.2159447","article-title":"Characteristics of Ocular Inflammatory Side Effects Associated with Immune Checkpoint Inhibitors in a Northern California Population","volume":"32","author":"Qian","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"108317","DOI":"10.1016\/j.clim.2019.108317","article-title":"Occurrence of Major Anti-Retinal Autoantibodies Associated with Paraneoplastic Autoimmune Retinopathy","volume":"210","author":"Adamus","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_25","first-page":"140","article-title":"Ipilimumab-Induced Ocular and Orbital Inflammation\u2014A Case Series and Review of the Literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12348-022-00321-2","article-title":"Ocular Adverse Events Associated with Immune Checkpoint Inhibitors, a Scoping Review","volume":"13","author":"Martens","year":"2023","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"ref_28","first-page":"173","article-title":"Clinical and Immunologic Characteristics of Melanoma-Associated Retinopathy Syndrome: Eleven New Cases and a Review of 51 Previously Published Cases","volume":"21","author":"Keltner","year":"2001","journal-title":"J. Neuro-Ophthalmol. Off. J. N. Am. Neuro-Ophthalmol. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00262-021-02875-x","article-title":"Normalization of Electroretinogram and Symptom Resolution of Melanoma-Associated Retinopathy with Negative Autoantibodies after Treatment with Programmed Death-1 (PD-1) Inhibitors for Metastatic Melanoma","volume":"70","author":"Khaddour","year":"2021","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/3\/154\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:32:48Z","timestamp":1760034768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/3\/154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["reports8030154"],"URL":"https:\/\/doi.org\/10.3390\/reports8030154","relation":{},"ISSN":["2571-841X"],"issn-type":[{"type":"electronic","value":"2571-841X"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}